Publications

Petosemtamab (MCLA-158)

Date	Publication
Apr 17, 2023	MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced gastric/esophageal adenocarcinoma (GEA) Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Apr 17, 2023	ORAL PRESENTATION: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC) Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Apr 25, 2022	Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors Bram Herpers, Berina Eppink, Mark I. James, Carme Cortina, Adrià Cañellas-Socias, Sylvia F. Boj, Xavier Hernando-Momblona, Dominik Glodzik, Rob C. Roovers, Marc van de Wetering, Carina Bartelink Clements, Vanessa Zondag van der Zande, Jara García Mateos, Kuan Yan, Lucia Salinaro, Abdul Basmeleh, Szabolcs Fatrai, David Maussang, Jeroen J Lammerts van Bueren, Irene Chicote, Garazi Serna, Laia Cabellos, Lorena Ramírez, Paolo Nuciforo, Ramon Salazar, Cristina Santos, Alberto Villanueva, Camille Stephan-Otto-Attolini, Elena Sancho, Hector G. Palmer, Josep Tabernero, Michael R. Stratton, John de Kruif, Ton Logtenberg, Hans Clevers, Leo S. Price, Robert Vries, Eduard Batlle, Mark Throsby Nature Cancer DOI 10.1038/s43018-022-00359-0
Oct 07, 2021	Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma Presented at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (2021)
Jan 15, 2021	Phase I dose escalation study of MCLA-158, a first in class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC) Poster presented at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
Apr 01, 2017	Identification and characterisation of MCLA-158 as an anti-EGFRxLGR5 bispecific antibody that potently inhibits patient-derived CRC organoid growth Rob C. Roovers¹, Bram Herpers², Mark James³, Berina Eppink¹, Carme Cortina³, David Maussang-Detaille¹, Ingrid Kolfschoten¹, Sylvia F. Boy⁴, Marc van de Wetering⁴, Wim de Lau⁵, Robert Doornbos¹, Carina Clements¹, Abdul Basmeleh¹, Willem Bartelink¹, Vanessa Zondag van de Zande¹, Kuan Yan², Lucia Salinaro², Lex Bakker¹, John de Kruif¹, Hans Clevers⁵, Robert Vries⁴, Eduard Batlle³, Leo Price² and Mark Throsby¹. ¹Merus NV, Utrecht, Netherlands; ²OcellO BV, Leiden, Netherlands; ³IRB Barcelona, Spain; ⁴HUB, Utrecht, Netherlands; ⁵The Hubrecht Institute, Utrecht, Netherlands. Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.
Nov 04, 2015	Generation of Wnt- and mitogenic receptor binding bispecific antibodies to target cancer stem cells Berina Eppink¹, Rob Roovers¹, Bram Herpers², Wim de Lau³, Carina Clements¹, Vanessa Zondag van der Zande¹, Abdul Basmeleh¹, Willem Bartelink¹, Marc van de Wetering^3,4, Robert Vries^3,4, Leo Price², John de Kruif¹, and Mark Throsby¹. ¹Merus BV Utrecht, Netherlands; ²OcellO BV, Leiden, Netherlands; ³Hubrecht Institute, Utrecht, Netherlands; ⁴HUB, Utrecht, Netherlands. Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA.

Zenocutuzumab (MCLA-128)

Date	Publication
Apr 08, 2024	Zenocutuzumab, a HER2 × HER3 bispecific antibody, is effective in cancer models with high NRG1 expression Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Feb 14, 2024	The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions Dong-Wan Kim‡, Alison M Schram‡, Antoine Hollebecque, Kazumi Nishino, Teresa Macarulla, Sun Young Rha, Michaël Duruisseaux, Stephen V Liu, Mohammed Najeeb Al Hallak, Kumiko Umemoto, Claas Wesseler, James M Cleary, Christoph Springfeld, Cindy Neuzillet, Andrew Joe, Shekeab Jauhari, Jim Ford & Koichi Goto Future Medicine doi: 10.2217/fon-2023-0824
Dec 02, 2023	Durable efficacy of zenocutuzumab, a HER2 × HER3 bispecific antibody, in advanced NRG1 fusion–positive (NRG1+) non-small cell lung cancer (NSCLC) Presented at the European Society for Medical Oncology (ESMO) Asia Congress 2023
Oct 21, 2023	Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) Presented at the European Society for Medical Oncology (ESMO) Congress 2023
Oct 20, 2023	Durable efficacy of zenocutuzumab, a HER2 × HER3 bispecific antibody, in advanced NRG1 fusion–positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC) Poster presented at the European Society for Medical Oncology (ESMO) Congress 2023
Aug 18, 2022	Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor Elisa Fontana , MD, PhD; Gonzalo Torga , MD; Raluca Fostea , MD; Susan Cleator, MD; Ernesto Wasserman, MD; Anastasia Murat, PhD; and Hendrik-Tobias Arkenau , MD, PhD DOI: 10.1200/PO.21.00446 JCO Precision Oncology no. 6 (2022) e2100446. Published online August 17, 2022.
Jun 05, 2022	Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) cancers Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Feb 08, 2022	Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements Alison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J Sisso, Marissa S Mattar, Allan J.W Lui, Morana Vojnic, Sara H Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, Marie N O'Connor, Cecile A. W Geuijen, Ron CJ Schackmann, Jeroen J. Lammerts van Bueren, Ernesto Wasserman, Elisa de Stanchina, Eileen M O'Reilly, Marc Ladanyi, Alexander Drilon and Romel Somwar Cancer Discovery DOI: 10.1158/2159-8290.CD-21-1119
Dec 10, 2021	Updated analysis of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in patients with HER2 positive/amplified (HER2+) metastatic breast cancer who progressed on previous anti-HER2 ADCs Presented at the San Antonio Breast Cancer Symposium (SABCS) 2021
Oct 07, 2021	Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusions Presented at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (2021)
Jun 04, 2021	Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions Presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Apr 10, 2021	The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions Poster presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Apr 10, 2021	Zenocutuzumab, an antibody that can overcome HER3 mediated NRG1 signaling in tumor cells by docking on HER2. Poster presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Jan 28, 2021	Phase 2 study of Zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors Presented at the IASLC 2020 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer
May 29, 2020	NRG1 fusion-driven cancers: A systematic literature review and meta-analysis. Viktoriya Stalbovskaya, Ernesto Wasserman, Jon Fryzek, Lauren C Bylsma, and L. Andres Sirulnik. Journal of Clinical Oncology (2020)
May 29, 2020	A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors TiP poster presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting
May 29, 2020	Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer patients with ET-resistant disease who had progressed on a cyclin-dependent kinase (CDK) 4/6 inhibitor Poster presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting
May 29, 2020	Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab and vinorelbine in HER2-amplified metastatic breast cancer patients (MBC) who had progressed on anti-HER2 antibody drug conjugates (ADCs) Poster presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting
Jan 31, 2020	Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors Aurelia H. M. de Vries Schultink, Kees Bol, Robert P. Doornbos, Anastasia Murat, Ernesto Wasserman, Thomas P. C. Dorlo, Jan H. M. Schellens, Jos H. Beijnen, Alwin D. R. Huitema. Clinical Pharmacokinetics, (2020).
Oct 27, 2019	Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers Alison M Schram¹, Eileen M O'Reilly¹, Romel Somwar¹, Ryma Benayed¹, Sara Shameem¹, Thrusha Chauhan¹, Jean Torrisi¹, Jim Ford², David Maussang², Ernesto Wasserman², Marc Ladanyi¹, David M Hyman¹, L Andres Sirulnik², Alexander E Drilon¹. ¹Memorial Sloan Kettering, NY, USA; ²Merus N.V., Utrecht, Netherlands. Poster presented at the AACR-NCI-EORTC 2019 Congress, Boston, MA, USA.
Oct 27, 2019	Clinical proof-of-concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers Alison M Schram¹, Eileen M O'Reilly¹, Romel Somwar¹, Ryma Benayed¹, Sara Shameem¹, Thrusha Chauhan¹, Jean Torrisi¹, Jim Ford², David Maussang², Ernesto Wasserman², Marc Ladanyi¹, David M Hyman¹, L Andres Sirulnik², Alexander E Drilon¹. ¹Memorial Sloan Kettering, NY, USA; ²Merus N.V., Utrecht, Netherlands. Poster presented at the AACR-NCI-EORTC 2019 Congress, Boston, MA, USA.
Sep 29, 2019	A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors AM Schram¹, A Drilon¹, T Macarulla Mercade², EM O'Reilly¹, J Rodon³, B Wolpin⁴, S-HI Ou⁵, D-W Kim⁶, JCH Yang⁷, YC Lam⁸, A Varga⁹, AJ de Langen¹⁰, P Witteveen¹¹, V Boni¹², G Cerea¹³, M Duruisseaux¹⁴, SV Liu¹⁵, E Wasserman¹⁶, DM Hyman¹, J Tabernero². ¹Memorial Sloan Kettering/Weill Cornell Medical College, NY, USA; ²Vall d'Hebron University Hospital/VHIO, Barcelona, Spain; ³MD Anderson Cancer Center, TX, USA; ⁴Dana-Farber Cancer Institute, MA, USA; ⁵University of California Irvine, CA, USA; ⁶Seoul National University Hospital, Seoul, Republic of Korea ; ⁷National Taiwan University Cancer Center/Hospital, Taipei, Taiwan; ⁸National Cancer Centre Singapore, Singapore; ⁹Gustave Roussy, Villejuif, France; ¹⁰Netherlands Cancer Institute, Netherlands, ¹¹UMC Utrecht Cancer Center, Netherlands; ¹²START Madrid-CIOCC/University Hospital Sanchinarro, Madrid, Spain; ¹³Niguarda Cancer Center, Ospedale Niguarda/Università degli Studi di Milano, Italy; ¹⁴Hôpital Louis Pradel-Hospices Civils de Lyon, France; ¹⁵Lombardi Cancer Center Georgetown University, Washington, USA; ¹⁶Merus N.V., Utrecht, Netherlands. Poster presented at the European Society for Medical Oncology (ESMO) 2019 Congress, Barcelona, Spain.
Oct 21, 2018	Phase 1/2 study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: overall safety at the recommended Phase 2 dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ) Maria Alsina¹, Andrea Varga², Alessio Amatu³, Jan H.M. Schellens⁴, Els Witteveen⁵, Valentina Boni⁶, Victor Moreno⁷, Paolo Nuciforo¹, Aurelia de Vries Schultink⁴, Kees Bol⁸, Afrodite Lourbakos⁸, Marina Magin Ferrer⁸, and Ernesto Wasserman⁸. ¹Vall d'Hebron University Hospital, Barcelona, Spain; ²DITEP, Gustave Roussy, Villejuif, France; ³Niguarda Hospital, Milan, Italy; ⁴Netherlands Cancer Institute, Amsterdam, Netherlands; ⁵University Medical Center Utrecht, Netherlands; ⁶START CIOCC, Madrid, Spain; ⁷START - FJD, Madrid, Spain; ⁸Merus NV, Utrecht, Netherlands. Poster presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany.
May 14, 2018	Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade Cecile A.W. Geuijen, Camilla De Nardis, David Maussang, Eric Rovers, Tristan Gallenne, Linda J.A. Hendriks, Therese Visser, Roy Nijhuis, Ton Logtenberg, John de Kruif, Piet Gros, and Mark Throsby. Cancer Cell, 33, 922-936 (2018).
May 05, 2018	Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose Aurelia H. M. de Vries Schultink, Robert P. Doornbos, Alexander B. H. Bakker, Kees Bol, Mark Throsby, Cecile Geuijen, David Maussang, Jan H. M. Schellens, Jos H. Beijnen, and Alwin D. R. Huitema. Investigational New Drugs, 36, 1006-1015 (2018).
Jun 02, 2017	First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3; final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC) Maria Alsina¹, Valentina Boni², Aurelia de Vries Schultink³, Victor Moreno⁴, Kees Bol⁵, Martine Westendorp⁵, L. Andres Sirulnik⁵, Josep Tabernero¹, and Emiliano Calvo².¹Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; ²START Madrid CIOCC, Hospital HM Universitario Sanchinarro, Madrid, Spain; ³Netherlands Cancer Institute, Amsterdam, Netherlands; ⁴START - FJD, Madrid, Spain; ⁵Merus NV, Utrecht, Netherlands. Poster presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, USA.
Apr 01, 2017	The binding mode of the bispecific anti-HER2xHER3 antibody MCLA-128 is responsible for its potent inhibition of HRG-driven tumorigenesis David Maussang¹, Camilla De Nardis², Linda Hendriks¹, Carina Bartelink-Clements¹, Nellie Nieuwenhuizen¹, Eric Rovers¹, Tristan Gallenne¹, Robert Doornbos¹, Lex Bakker¹, Ton Logtenberg¹, John de Kruif¹, Piet Gros², Cecile Geuijen¹, and Mark Throsby¹.¹Merus NV, Utrecht, Netherlands; ²Utrecht University, Netherlands. Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.
Apr 22, 2015	Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2:HER3 heterodimer Cecile Geuijen, Eric Rovers, Tristan Gallenne, David Maussang-Detaille, Arjen Kramer, Nellie Nieuwenhuizen, Katinka van Zoest, Roy Nijhuis, Therese Visser, Renate den Blanken-Smit, Abdul Basmeleh , Willem Bartelink, Vanessa Zondag-van der Zande, Carina Clements, Linda Kaldenberg, Pieter Fokko van Loo, Rob Roovers, Leo Price, Stefan Braam, Robert Doornbos, Setareh van Driel Shamsili, Lex Bakker, Ton Logtenberg, John de Kruif, Mark Throsby. Poster presented at the American Association for Cancer Research (AACR) 2015 Annual Meeting, Philadelphia, Pennsylvania, USA.

MCLA-129

Date	Publication
Dec 02, 2023	ORAL PRESENTATION: Efficacy and safety of MCLA-129, an EGFR x c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC) Presented at the European Society for Medical Oncology (ESMO) Asia Congress 2023
Dec 02, 2023	Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell carcinoma (HNSCC) Presented at the European Society for Medical Oncology (ESMO) Asia Congress 2023
Apr 18, 2023	Preclinical evaluation of MCLA-129, a bispecific antibody targeting EGFR and c-MET on solid tumor cells, in comparison with amivantamab Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Oct 26, 2022	MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study Presented at EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics (2022)
Apr 10, 2022	Mechanism of action of MCLA-129, a bispecific antibody that targets EGFR and c-MET and impairs growth of EGFR exon 20 insertion mutant non-small cell lung cancer Poster presented at the American Association for Cancer Research Annual Meeting 2022
Apr 10, 2021	The bispecific antibody MCLA-129 impairs NSCLC tumor growth by targeting EGFR and c-MET, inhibiting ligand-induced signaling and promoting ADCC and ADCP Poster presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Oct 29, 2019	Preclinical evaluation of MCLA-129: a bispecific antibody targeting c-MET and EGFR Cecile Geuijen¹, Mario di Matteo^2,3, Sarah Trusso Cafarello^2,3, Tristan Gallenne¹, Roy Nijhuis¹, Therese Visser¹, Willem Bartelink¹, Carina Bartelink-Clements¹, Vanessa Zondag-van der Zande¹, Eric Rovers1, Karin de Cortie¹, Linda Kaldenberg-Hendriks¹, Berina Eppink¹, Rinse Klooster¹, John de Kruif¹, Massimiliano Mazzone^2,3, Mark Throsby¹. ¹Merus N.V. Utrecht, The Netherlands; ²Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium; ³Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, Department of Oncology, KU Leuven, Belgium. Poster presented at the AACR-NCI-EORTC 2019 Congress, Boston, MA, USA.

MCLA-145

Date	Publication
Dec 06, 2021	Phase I Dose Escalation Study of MCLA-145, a Bispecific Antibody Targeting CD137 and PD-L1 in Solid Tumors Presented at ESMO Immuno-Oncology (ESMO IO) Congress 2021
Jul 21, 2021	A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade Cecile Geuijen, Paul Tacken, Liang-Chuan Wang, Rinse Klooster, Pieter Fokko van Loo, Jing Zhou, Arpita Mondal, Yao-bin Liu, Arjen Kramer, Thomas Condamine, Alla Volgina, Linda J. A. Hendriks, Hans van der Maaden, Eric Rovers, Steef Engels, Floris Fransen, Renate den Blanken-Smit, Vanessa Zondag-van der Zande, Abdul Basmeleh, Willem Bartelink, Ashwini Kulkarni, Wilfred Marissen, Cheng-Yen Huang, Leslie Hall, Shane Harvey, Soyeon Kim, Marina Martinez, Shaun O'Brien, Edmund Moon, Steven Albelda, Chrysi Kanellopoulou, Shaun Stewart, Horacio Nastri, Alexander B. H. Bakker, Peggy Scherle, Ton Logtenberg, Gregory Hollis, John de Kruif, Reid Huber, Patrick A. Mayes & Mark Throsby Nature Communications volume 12, Article number: 4445 (2021)
Nov 09, 2020	MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells Poster presented at the Society for Immunotherapy of Cancer's (SITC) 2020 Annual Meeting.
Nov 09, 2020	MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that does not show signs of peripheral toxicity in preclinical models Poster presented at the Society for Immunotherapy of Cancer's (SITC) 2020 Annual Meeting.
Mar 31, 2019	An unbiased screen identifies a CD137xPD-L1 bispecific IgG1 antibody with unique T cell activation and binding properties Cecile A. Geuijen¹, Paul Tacken¹, Rinse Klooster¹, Horacio Nastri², Shaun Stewart², Jing Zhou², Steve Wang², Cheng-Yen Huang², Arjen Kramer¹, Linda Kaldenberg-Hendriks¹, John de Kruif¹, Renate den Blanken-Smit¹, Vanessa Zondag-van de Zande¹, Abdul Basmeleh¹, Willem Bartelink¹, Patrick Mayes², Gregory Hollis², Reid Huber², Mark Throsby¹. ¹Merus NV, Utrecht, Netherlands; ²Incyte Corporation, Wilmington, DE. Poster presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, Atlanta, GA, USA.
Mar 31, 2019	A bispecific Fc-silenced IgG1 antibody (MCLA-145) requires PD-L1 binding to activate CD137 Patrick Mayes¹, Paul Tacken², Steve Wang¹, Pieter-Fokko van Loo², Thomas Condamine¹, Hans van der Maaden², Eric Rovers², Steef Engels², Floris Fransen², Ashwini Kulkarni¹, Yao-bin Liu¹, Arpita Mondal¹, Leslie Hall¹, Soyeon Kim³, Marina Martinez³, Shaun O'Brien³, Edmund Moon³, Steven Albelda³, Peggy Scherle¹, Gregory Hollis¹, Reid Huber¹, Mark Throsby², Cecile A. Geuijen². ¹Incyte Corporation, Wilmington, DE;²Merus NV, Utrecht, Netherlands; ³University of Pennsylvania, Philadelphia. Poster presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, Atlanta, GA, USA.

CD3 T Cell Engagers

Date	Publication
Jun 12, 2020	Update from the ongoing phase I multinational study of MCLA-117, a bispecific CLEC12A x CD3 T-cell engager, in patients with acute myelogenous leukemia Poster presented at the virtual edition of the European Hematology Association (EHA) 2020 Annual Congress.
Jun 12, 2020	T cell engaging bispecific antibodies generated from a novel, large and diverse CD3 panel demonstrate functionality uncoupled from affinity Poster presented at the virtual edition of the European Hematology Association (EHA) 2020 Annual Congress.
Jul 09, 2019	MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis Pieter Fokko van Loo, Basav N. Hangalapura, Soley Thordardottir, John D. Gibbins, Henrike Veninga, Linda J. A. Hendriks, Arjen Kramer, Rob C. Roovers, Marij Leenders, John de Kruif, Robert P. Doornbos, Andres Sirulnik, Mark Throsby, Ton Logtenberg, Harry Dolstra & Alexander B. H. Bakker. Expert Opinion on Biological Therapy, 19, 721-733 (2019).
Nov 09, 2016	MCLA-117, a CLEC12AxCD3 bispecific IgG targeting a leukemic stem cell antigen, induces T cell mediated AML blast lysis Pieter Fokko van Loo¹, Henrike Veninga¹, Harry Dolstra², and Lex Bakker¹. ¹Merus NV, Utrecht, Netherlands; ²Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands. Poster presented at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting, National Harbor, MD, USA.

Merus Platform Technology

Date	Publication
Jun 27, 2017	A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1 Camilla De Nardis, Linda J.A. Hendriks, Emilie Poirier, Tudor Arvinte, Piet Gros, Alexander B.H. Bakker, and John de Kruif. Journal of Biological Chemistry, 292, 14706-14717 (2017).
Sep 26, 2016	Generation of immuno-modulatory receptor binding bispecific antibodies to modulate tumor immunity Rinse Klooster, Cecile Geuijen, Renate den Blanken-Smit, Mireille Koenders, Annette Wensink, Eric Rovers, Hans van der Maaden, Steef Engels, Tristan Gallenne, Therese Visser, Carina Bartelink-Clements, Katinka van Zoest, Roy Nijhuis, Abdul Basmeleh, Willem Bartelink, Vanessa Zondag-van der Zande, Arjen Kramer, Linda Kaldenberg, Berina Eppink, Rob Roovers, Paul Tacken, Lex Bakker, Pieter Fokko van Loo, John de Kruif, and Mark Throsby. Poster presented at the International Congress on Immunotherapies in Cancer (ICIC) 2016 Annual Meeting, New York, NY, USA.
Nov 11, 2013	Complex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry Natalie J. Thompson, Linda J.A. Hendriks, John de Kruif, Mark Throsby, and Albert J.R. Heck. mAbs, 6, 197-203 (2013).
Aug 10, 2012	Qualitative and semiquantitative analysis of composite mixtures of antibodies by native mass spectrometry Sara Rosati, Natalie J. Thompson, Arjan Barendregt, Linda J. A. Hendriks, Alexander B. H. Bakker, John de Kruif, Mark Throsby, Esther van Duijn, and Albert J. R. Heck. Analytical Chemistry, 84, 7227-7232 (2012).
Jun 21, 2010	Generation of stable cell clones expressing mixtures of human antibodies John de Kruif, Arjen Kramer, Roy Nijhuis, Vanessa van der Zande, Renate den Blanken, Carina Clements, Therese Visser, Rob Keehnen, Marcel den Hartog, Mark Throsby, and Ton Logtenberg. Biotechnology and Bioengineering, 106, 741-750 (2010).
Apr 03, 2009	Human immunoglobulin repertoires against tetanus toxoid contain a large and diverse fraction of high-affinity promiscuous VH genes John de Kruif, Arjen Kramer, Therèse Visser, Carina Clements, Roy Nijhuis, Freek Cox, Vanessa van der Zande, Renate Smit, Daniel Pinto, Mark Throsby, and Ton Logtenberg. Journal of Molecular Biology, 387, 548-558 (2009).